Introduction {#sec0005}
============

States of wakefulness, which broadly influence behaviour and cognitive function, are maintained by basal forebrain, hypothalamic, thalamic and brainstem neurons via a range of chemical and peptide transmitters ([@bib0130]). Among these, the neuropeptide, relaxin-3, has emerged as a highly-conserved modulator of arousal in vertebrate species. While primarily located within the brainstem *nucleus incertus* (NI) ([@bib0030]), relaxin-3 neurons are also found in the periaqueductal grey (PAG), pontine raphe nucleus and a region dorsal to the substantia nigra in rat ([@bib0330]), mouse ([@bib0310]) and macaque ([@bib0235]) brain. The vast majority of NI neurons produce γ-aminobutyric acid (GABA), with around one-third of GABAergic NI neurons expressing relaxin-3 ([@bib0215], [@bib0205]). Various other neuropeptides, including cholecystokinin ([@bib0165]; [@bib0260]) and neuromedin B ([@bib0055]), along with the calcium-binding proteins, calbindin and calretinin ([@bib0265]; [@bib0215]), are also expressed in the NI, indicating a specialised role for relaxin-3 neurons amongst these heterogenous populations.

The anatomical location and innervation pattern of the NI ([@bib0090]; [@bib0260]) suggest relaxin-3 signalling from this nucleus is driven by integrated inputs related to behavioural planning, and in turn, modulates appropriate cognitive activity and responses. For example, blockade of corticotropin-releasing factor-1 (CRF~1~) ([@bib0350]) or orexin-2 (OX~2~) ([@bib0145]) receptors attenuates stress-induced relapse to alcohol-seeking in alcohol-preferring (iP) rats, with NI relaxin-3 neurons expressing receptors for, and being responsive to, these peptides ([@bib0210]; [@bib0020]). 5-HT~1A~ serotonin ([@bib0250]) and D~2~ dopamine ([@bib0170]) receptors are also expressed by relaxin-3 NI neurons, and have been implicated in anxiety ([@bib0180]) and locomotor ([@bib0170]) behaviour, respectively. These various integrated inputs are conveyed by ascending relaxin-3 projections to mid- and fore-brain regions containing neurons expressing relaxin-family peptide receptor 3 (RXFP3) ([@bib0215]; [@bib0310]).

RXFP3 is the cognate receptor for relaxin-3 ([@bib0195]) and triggers G~i/o~-protein-mediated inhibition of cyclic adenosine monophosphate (cAMP) production in response to relaxin-3 binding *in vitro* ([@bib0195]; [@bib0345]). Similarly, electrophysiological studies of RXFP3 activation in brain slices typically identified membrane hyperpolarisation and neuronal inhibition ([@bib0015]; [@bib0140]; [@bib0040]). As such, relaxin-3 signalling, likely working in conjunction with co-expressed, fast-acting GABA neurotransmission ([@bib0215]), appears to promote arousal, in part through the selective disinhibition of key neural networks ([@bib0225]). One such network, the septohippocampal pathway, contains inhibitory, parvalbumin-positive medial septal neurons and hippocampal somatostatin- and parvalbumin-positive interneurons that express RXFP3 in rat and mouse brain ([@bib0100]; [@bib0005]; [@bib0285]; [@bib0105]). Selective blockade or deletion of RXFP3 ([@bib0230]; [@bib0100], [@bib0105]) in these regions impairs spatial memory and associated hippocampal theta rhythm, to which relaxin-3 NI neurons are strongly phase-locked ([@bib0210]). Social recognition is also influenced by relaxin-3 signalling, as RXFP3 agonists, delivered by viral vector-mediated expression in ventral hippocampus ([@bib0285]) or intracerebroventricular infusion ([@bib0010]), reduce interactions of rats with novel conspecifics.

Additional pharmacological studies targeting RXFP3 have shown effects on interrelated anxiety ([@bib0280]; [@bib0370]), feeding ([@bib0245]; [@bib0300]) and motivated ([@bib0305]) behaviours, most likely via actions within limbic and hypothalamic networks ([@bib0140]). A key role for this system in innate anxiety is also highlighted by independent relaxin-3 and RXFP3 gene knock-out mouse lines, which display a small, but consistent, decrease in anxiety behaviour ([@bib0355]; [@bib0125]). Considering these and other described functions, in addition to its discrete expression profile and neuromodulatory nature, the relaxin-3/RXFP3 system offers considerable potential as a therapeutic target (see [@bib0315]; [@bib0175]; [@bib0240] for review). In advancing our understanding of relaxin-3 neural circuitry, which to date has largely relied on pharmacological and gene knock-out models, we sought to take advantage of modern transgenic approaches. Recent chemo- ([@bib0205]) and opto-genetic ([@bib0325]) manipulations have provided powerful insights into the ability of NI neurons to fine-tune behavioural responses and memory formation. Our laboratory has also established adeno-associated viral (AAV) vectors for efficient transgene delivery into NI neurons ([@bib0035]; [@bib0205]). However, these experiments targeted either GABAergic NI neurons or the entire nucleus, thus affecting multiple populations, including but not limited to, relaxin-3 neurons ([@bib0215]; [@bib0220]).

The present study therefore aimed to identify a promoter sequence capable of selectively driving transgene expression in relaxin-3 NI neurons following viral vector transduction. [@bib0335] are, to our knowledge, the only other investigators to describe a relaxin-3 promoter. Their experiments reported promoter activity from a 1.8 kilobase (kb) sequence, located directly 5′ of the mouse relaxin-3 gene, which was upregulated following stimulation of the CRF~1~ receptor and downstream cAMP-protein kinase A (PKA) pathway. Although these experiments demonstrated this sequence could drive enhanced green fluorescent protein (EGFP) expression in cultured neuroblastoma cells expressing relaxin-3, they did not determine the cell-type specificity of the observed promoter activity. As such, we assessed the ability of an approximately analogous 1736 base pair (bp) region of rat genomic DNA to provide cell-type specific transduction of relaxin-3 NI neurons. In addition, we have discovered that tropomyosin receptor kinase A (TrkA), a high-affinity receptor for nerve-growth factor (NGF), is exclusively co-expressed with relaxin-3 in rat NI neurons (see e.g. [@bib0320] and Results). In light of existing evidence for cell-type specific activity from human or mouse TrkA promoter and enhancer elements in neuroblastoma cell lines ([@bib0045]; [@bib0290]) and mouse trigeminal and dorsal root ganglia during development ([@bib0200]), we also attempted to achieve targeted AAV transduction of relaxin-3 neurons in rat NI using an 880 bp TrkA promoter sequence.

In contrast to previous data obtained using different experimental conditions, we observed widespread non-specific transduction of neurons in the rat NI and neighbouring dorsal tegmental nuclei, following stereotaxic injection of an AAV vector expressing mCherry using the 880 bp TrkA promoter. However, a similar AAV vector, engineered to express mCherry under the control of the 1736 bp rat relaxin-3 promoter, was able to transduce relaxin-3 NI neurons with 98% specificity for at least eight weeks following transgene delivery.

Experimental procedures {#sec0010}
=======================

Animals {#sec0015}
-------

All experiments were approved by The Florey Institute of Neuroscience and Mental Health Animal Ethics Committee and conducted in accordance with ethical guidelines provided by the National Health and Medical Research Council of Australia. Sprague-Dawley rats (250--300 g males, Animal Resources Centre, Canning Vale, WA, Australia) were single-housed with free access to water and standard chow under ambient conditions (21 °C) and a 12 h light:dark cycle (lights on 07:00). Every effort was made to minimize the number of rats used and any stress resulting from the procedures described.

Relaxin-3 and TrkA promoter design {#sec0020}
----------------------------------

Pairwise alignments of rat genomic sequences (Jul. 2014 (RGSC 6.0/rn6) assembly) ([@bib0115]; [@bib0080]) with other vertebrate genomes, including mouse (Dec. 2011 (GRCm38/mm10) assembly) ([@bib0255]) and human (Dec. 2011 (GRCh38/hg38) assembly) ([@bib0185]), were visualised using the UCSC Genome Browser's chain track feature ([@bib0155]). Based on the location of two regions upstream of the relaxin-3 gene, conserved in rodents but not primates, we initially attempted to isolate a 3.5 kb sequence from rat genomic DNA using polymerase chain reaction (PCR). However, 1.8 kb of poorly conserved DNA between these regions was skipped during PCR amplification (Supplementary Fig. 1A), resulting in a 1736 bp relaxin-3 promoter amplicon. Given that the conserved regions of interest were retained, we proceeded to characterise this 1736 bp sequence. Similar genomic comparisons using the UCSC Genome Browser were performed for the TrkA promoter region, revealing a high degree of sequence conservation in the non-coding region between the closely adjacent TrkA and insulin receptor-related protein (INSRR) genes (Supplementary Fig. 1B). Additional consideration was given to incorporate regions of rat genome analogous to minimal promoter and enhancer elements described for mouse ([@bib0290]; [@bib0200]) and human ([@bib0045]), resulting in selection of an 880 bp TrkA promoter region for characterisation (synthesised by GenScript (Piscataway, NJ, USA)). Data presented in Supplementary Fig. 1 were adapted from BLAT searches ([@bib0150]) of each promoter against the rat genome (Jul. 2014 (RGSC 6.0/rn6) assembly) in the UCSC Genome Browser.

Generation of plasmid vectors {#sec0025}
-----------------------------

Plasmids containing recombinant AAV vector genomes, with mCherry as a marker for promoter activity, were prepared using the Gateway cloning system, as described by [@bib0360]. To facilitate this, a Gateway-compatible AAV backbone plasmid (pAM-Gateway) was created using SpeI and HindIII cut sites to replace CAG promoter and EGFP coding sequences of pAM-DCA-EcoRI-EGFP ([@bib0035]) with an attR1-R2 cloning cassette. The 1736 bp rat relaxin-3 promoter sequence was cloned using forward (5′-attB1-CCTGCAAACTTGTCTGTGTAC-3′) and reverse (5′-attB5r-CAGCTGAGATGCCTGCGA-3′) primers. Additional forward (5′-attB1-GAACGGTTCCCAGCTCACACGTCCG-3′) and reverse (5′-attB5r-CGCGGCGGCGCCCGCCTAG-3′) primers were used to amplify the 880 bp rat TrkA promoter sequence. pENTR-L1-Rln3-R5 and pENTR-L1-TrkA-R5 plasmids were created by recombination of respective PCR products (50 fmol) with pDONR-P1-P5r. Further recombination steps, involving 10 fmol of either pENTR-L1-Rln3-R5 or pENTR-L1-TrkA-R5, with 10 fmol pENTR-L5-mCherry-L2 and 20 fmol of pAM-Gateway destination vector, produced pAM-Rln3-mCherry and pAM-TrkA-mCherry plasmids. Each recombination reaction used Clonase™II reagents (Life Technologies, Mulgrave, VIC, Australia) and was incubated at 25 °C for 16 h. pDONR-P1-P5r, pENTR-L5-mCherry-L2 and plasmid containing attR1-R2 cloning cassette, used in generating pAM-Gateway, were a gift from Dr Melanie White (A\*STAR, Singapore). Constructs containing PCR amplified promoter inserts were verified by Sanger sequencing (Australian Genome Research Facility, Melbourne, VIC, Australia).

AAV vector production and titration {#sec0030}
-----------------------------------

Mosaic serotype 1/2 AAV vectors were produced as described ([@bib0375]; [@bib0075]). In brief, genomes from pAM-TrkA-mCherry or pAM-Rln3-mCherry were packaged into AAV1/2 capsids by co-transfection into HEK293FT cells with pDPI and pDPII plasmids ([@bib0095]). Harvested vectors were purified by iodixanol gradient centrifugation and the titre, reported as genomic copies (gc) per ml, was determined using quantitative PCR with primers against the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) sequence, as described ([@bib0205]).

Stereotaxic injection of colchicine or AAV vectors {#sec0035}
--------------------------------------------------

Rats were placed in an enclosed chamber and anaesthesia induced by inhalation of 4% isoflurane before transfer to a stereotaxic frame (Kopf Instruments, Tujunga, CA, USA). Anaesthesia was maintained during surgical procedures with 2--3% isoflurane in air, delivered via a rat anaesthetic mask at 200 ml/min. Depth of anaesthesia was verified regularly by lack of eye-blink reflex in response to medial canthus touch and lack of withdrawal response to firm hind paw pinch. Body temperature was maintained throughout surgery with a heat pad. Rats were administered meloxicam intraperitoneally (1.5 mg/kg; Boehringer-Ingelheim, St Joseph, MO, USA), and bupivacaine subcutaneously at the top of the scalp (0.5% in sterile water), prior to an incision to expose the skull surface. A burr hole was drilled through the skull based on stereotaxic coordinates ([@bib0270]) as detailed below.

In studies to maximise the level of peptide and protein accumulation in the soma of NI neurons for the comparative immunohistochemical detection of relaxin-3 and TrkA, a cohort of rats (n = 5) were treated with intracerebroventricular colchicine. An injector needle (29 G) attached to polyethylene tubing connected to a 10 μl Hamilton syringe (Harvard Apparatus, Holliston, MA, USA) mounted on an infusion pump (11-Plus, Harvard Apparatus) was used to deliver colchicine (80 μg in 5 μl sterile saline) at a rate of 1 μl/min to the right lateral cerebral ventricle (AP -0.2 mm, ML + 1.5 mm, DV -4 mm from bregma). To minimise reflux of injectate up the cannula, the needle was left in place for 10 min and then withdrawn.

In separate cohorts of rats, promoter activity was characterised by stereotaxic injection of AAV vectors into NI. Prior to injection, AAV1/2-Rln3-mCherry (1.86 × 10^11^ gc/ml) or AAV1/2-TrkA-mCherry (2.04 × 10^11^ gc/ml) was mixed with an AAV1/2-CAG-EGFP vector (as described by [@bib0035]; 9.08 × 10^10^ gc/ml), to allow visualisation of total viral vector spread from the injection site, as reflected by EGFP expression driven by the non-specific CAG promoter. These values reflect the final titre of each vector when injected and account for dilution caused by mixing. Rats (n = 3 per group) received 0.4 μl bilateral injections of one of these viral vector mixtures, delivered into the NI at 0.1 μl/min using a pulled glass pipette attached to a 1 μl syringe. The coordinates used for injections were: AP -2.5 mm; ML ± 0.1 mm; DV -6.5 mm from lambda; incisor bar -12.5 mm. To minimise reflux, the pipette was left in place for 10 min after each injection, raised 1 mm and held in place for a further one min, before being slowly withdrawn.

Following colchicine or viral vector delivery, the incision was sutured, swabbed with providone iodine, and rats regained consciousness in a warm chamber. Rats were euthanised 24 h following colchicine infusion, whereas those that received viral vector injections were treated with meloxicam for a further 2 d following surgery, and maintained for 8 wk prior to sacrifice.

Histology and immunostaining {#sec0040}
----------------------------

Rats were euthanised by intraperitoneal injection of pentobarbitone (100 mg/kg) before transcardial perfusion with 300 ml of ice-cold phosphate-buffered saline (PBS, 0.1 M, pH 7.4) followed by 400 ml of 4% paraformaldehyde in PBS (PFA). Dissected brains were fixed in ice-cold 4% PFA for a further 1--2 h before undergoing cryoprotection by submersion in a 30% sucrose/PBS solution at 4 °C for 3 d.

For immunostaining and assessment of viral vector transduction in NI, coronal sections (40 μm) from bregma -10.4 mm to -8.4 mm ([@bib0270]) were collected free-floating in PBS. Sections were transferred to blocking buffer (10% v/v normal horse serum (NHS) in PBS with 0.1% Triton-X) and incubated for 1 h at room temperature with agitation. NHS blocked sections from colchicine-treated rats were incubated in PBS containing mouse anti-relaxin-3 (1:5; HK4-144-10 ([@bib0160]; [@bib0330]; [@bib0215])) and rabbit anti-TrkA (1:10,000; kindly provided by Dr Louis Reichardt, UCSF, CA, USA; ([@bib0060]; [@bib0320]; [@bib0120])) antibodies with 2% NHS and 0.1% Triton-X at 4 °C for 72 h. Some sections were incubated with *only* the mouse anti-relaxin-3 antiserum or the rabbit anti-TrkA antisera to check for non-specific interactions in the double-label studies. Coronal NI sections from rats that received AAV vector injections were incubated in PBS containing mouse anti-relaxin-3 (1:5; HK4-144-10) and rabbit anti-red fluorescent protein (1:1000; Rockland Immunochemicals, Limerick, PA, USA) antibodies with 2% NHS and 0.1% Triton-X for 24 h at 4 °C.

Sections were washed 3 × 10 min in PBS following primary antibody incubations. Sections were incubated in PBS containing Alexa Fluor-594-conjugated donkey anti-rabbit and Alexa Fluor-647-conjugated donkey anti-mouse antibodies (1:500 each; Jackson ImmunoResearch, West Grove, PA, USA) as well as bis-benzimide H (Hoechst) 33,342 (1 μg/ml; Sigma-Aldrich, Castle Hill, NSW, Australia) for 1 h at room temperature. Sections were washed 3 × 5 min in PBS, slide-mounted and coverslipped with Dako fluorescence mounting medium (Agilent Technologies, Santa Clara, CA, USA).

In studies to visualise NI-transduced neuronal projections in the medial septum (MS), 40 μm coronal sections from bregma +1.56 mm to 0.00 mm were collected and blocked with NHS as described. Following incubation in PBS containing 1:500 mouse anti-mCherry (Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA, USA) and 1:500 rabbit anti-GABA (Sigma-Aldrich) antibodies, with 2% NHS, 0.1% Triton-X and 0.5% thimerosal (Sigma-Aldrich) for 72 h at room temperature, sections were washed 3 × 10 min in PBS. A further 2 h incubation at room temperature in PBS solution containing 1:500 Alexa-594-conjugated donkey anti-mouse and Alexa-647 conjugated donkey anti-rabbit antibodies (Jackson ImmunoResearch) as well as bis-benzimide H (Hoechst) 33342 (1 μg/ml) preceded 3 × 5 min washes in PBS and slide-mounting as described.

Imaging and quantitative analysis {#sec0045}
---------------------------------

An LSM 780 Zeiss Axio Imager 2 laser scanning confocal microscope (Carl Zeiss AG, Oberkochen, Germany) was used to acquire images. To assess promoter activity in NI neurons, relaxin-3-immunoreactivity (IR) (Alexa Fluor-647) and mCherry-IR (Alexa Fluor-594), as well as Hoechst nuclear stain (to assist with cell counting) and innate EGFP, were imaged using a 20× air objective lens in every third section from bregma -9.00 mm to -9.84 mm for each rat. Centred on the midline directly ventral to the fourth ventricle, 1.57 mm × 1.19 mm images were collected using a stitching stage and Zen Black software (Carl Zeiss AG). Planes were collected at 3 μm intervals through the z-axis and used to produce maximum projection images in Fiji software ([@bib0295]), where manual cell counts and colocalisation analysis of fluorescent soma were also performed. Percentages calculated for the specificity and efficiency of viral vector transduction (see Results for further descriptions) are reported as mean ± standard error of the mean (SEM). High magnification images of relaxin-3-IR (Alexa Fluor-647) and TrkA-IR (Alexa Fluor-594) in NI, or mCherry-IR (Alexa Fluor-594), GABA-IR (Alexa Fluor-627), innate EGFP and Hoechst nuclear stain in MS, were collected using a 63× oil immersion objective lens, with images collected at 2 μm intervals through the z-axis. All microscopy data in figures presented are maximum intensity z-stack projections.

Results {#sec0050}
=======

Established and emerging transgenic techniques offer powerful approaches to understanding neural circuit structure and function. Such techniques have been applied in recent molecular and behavioural studies utlising viral vector injections for targeted NI expression in wild-type or transgenic rodents ([@bib0205]; [@bib0325]). However, these experiments affected multiple, heterogenous populations of NI neurons ([@bib0215]; [@bib0220]), highlighting the need for more selective methods of transgene expression. In the present study, we sought to identify a promoter sequence capable of selectively driving transgene expression in relaxin-3 NI neurons following AAV vector transduction. In addition to a conserved region upstream of the rat relaxin-3 gene coding sequence, we also characterised the activity of a promoter region for the TrkA receptor, which is selectively co-expressed with relaxin-3 in NI neurons. The promoter activity of each sequence, as reflected by mCherry expression in transduced neurons, was characterised against immunolabelling for the relaxin-3 peptide. Co-injection of a separate, EGFP-expressing vector allowed relaxin-3 and TrkA promoter activity to be compared with the constitutive CAG promoter, while also facilitating visualisation of AAV vector spread outside the NI.

Targeted transduction of rat relaxin-3 NI neurons using a novel relaxin-3 promoter {#sec0055}
----------------------------------------------------------------------------------

In these studies, data were collected from rats (n = 3) displaying neuronal transduction by AAV1/2-Rln3-mCherry and AAV1/2-CAG-EGFP ([Fig. 1](#fig0005){ref-type="fig"}A) distributed bilaterally throughout the NI ([Fig. 1](#fig0005){ref-type="fig"}B-E), with data excluded from rats in which off-target or limited spread of transduction was observed ([Fig. 1](#fig0005){ref-type="fig"}F). Neurons displaying fluorescence in individual optical wavelength channels for EGFP, mCherry-IR or relaxin-3-IR were counted, with further counts of neurons containing EGFP and/or mCherry-IR in addition to relaxin-3-IR also performed (Supplementary Table 1). The specificity (proportion of transduced cells expressing relaxin-3) and efficiency (proportion of total relaxin-3 population transduced) of each promoter was calculated from these cell counts (Supplementary Table 2, [Fig. 1](#fig0005){ref-type="fig"}G). Similar transduction efficiencies were observed between AAV1/2-Rln3-mCherry and AAV1/2-CAG-EGFP vectors, with a majority of relaxin-3-IR NI neurons displaying EGFP (73 ± 8%) and/or mCherry-IR (70 ± 2%) fluorescence. As expected, non-specific transduction by AAV1/2-CAG-EGFP was evident throughout the NI and in regions of some neighbouring nuclei (e.g. DTg, [Fig. 1](#fig0005){ref-type="fig"}B), leading to relaxin-3-IR detection in only 30 ± 5% of EGFP expressing neurons. Importantly, this viral vector spread outside the NI was only reflected by CAG promoter-driven EGFP expression, with mCherry expression under the control of the Rln3 promoter limited to the NI ([Fig. 1](#fig0005){ref-type="fig"}F). Of the total number of neurons transduced by AAV1/2-Rln3-mCherry, virtually all (98 ± 1%) were found to contain relaxin-3-IR ([Fig. 1](#fig0005){ref-type="fig"}G). This was despite non-specific transduction of closely adjacent NI neurons by AAV1/2-CAG-EGFP ([Fig. 1](#fig0005){ref-type="fig"}C-E), indicating that the targeted mCherry expression was dependent on promoter activity rather than viral vector tropism.Fig. 1*Neuronal transduction by AAV1/2-Rln3-mCherry*. **(A)** Schematic design of recombinant AAV genomes for AAV1/2-CAG-EGFP and AAV1/2-Rln3-mCherry vectors (*L-ITR*, left inverted terminal repeat; *WPRE*, woodchuck hepatitis virus post-transcriptional regulatory element; *polyA*, SV40 poly A sequence; *R-ITR*, right inverted terminal repeat). **(B)** Representative image of innate fluorescence produced by EGFP (green) and fluorescence produced by mCherry (red) and relaxin-3 (blue) immunoreactivity, eight weeks after stereotaxic injection of AAV1/2-CAG-EGFP and AAV1/2-Rln3-mCherry vectors targeting NI (*4V*, fourth ventricle; *DTg*, dorsal tegmental nucleus; *mlf*, medial longitudinal fasciculus; *NIc*, NI *pars compacta*; *NId*, NI *pars dissipata*). **(C--E)** Individual fluorescence channels from **(B)** are illustrated at higher magnification. Transduced neurons lacking relaxin-3 immunoreactivity (RLN3-IR) are indicated by green arrowheads (i.e., AAV1/2-CAG-EGFP transduced only). Note there are no AAV1/2-Rln3-mCherry-transduced neurons in the field that do not contain RLN3-IR) (*RFP-IR*, red fluorescent protein (mCherry) immunoreactivity). **(F)** Distribution of neurons transduced by AAV1/2-CAG-EGFP (green) or AAV1/2-Rln3-mCherry (red) vectors, with RLN3-IR (blue) at bregma -9.36 mm in the rats (n = 3) used in the analysis. **(G)** Quantification of promoter specificity (proportion of transduced neurons containing RLN3-IR (black circles)) and efficiency (proportion of total RLN3-IR neurons transduced (grey circles)). Data points for each variable represent individual rats (n = 3) and bars represent mean ± SEM.Fig. 1

AAV1/2-Rln3-mCherry transduction identifies direct NI relaxin-3 neuron input to GABAergic medial septum circuitry {#sec0060}
-----------------------------------------------------------------------------------------------------------------

Multiplex *in situ* hybridisation studies have shown that *Rxfp3* mRNA is strongly co-expressed with vesicular GABA transporter (*vGAT*) mRNA in MS neurons ([@bib0005]; [@bib0105]). In studies to build on these findings and demonstrate the utility of AAV1/2-Rln3-mCherry in mapping networks formed by relaxin-3 NI neurons, we labelled coronal sections through the MS of rats used in the analysis of promoter specificity for GABA- and mCherry-IR (n = 2 rats; [Fig. 2](#fig0010){ref-type="fig"}). Staining of MS sections for relaxin-3 was not undertaken, given the exclusive expression of mCherry in relaxin-3 NI neurons observed. Large fibres containing EGFP emanating from neurons transduced by the control AAV1/2-CAG-EGFP vector were densely concentrated in the medial septum/diagonal band complex (MS/DB; [Fig. 2](#fig0010){ref-type="fig"}A), consistent with neural tract-tracing studies of NI ([@bib0090]; [@bib0260]; [@bib0230]); confirming that ascending efferent projections from the NI pass through and/or terminate in the MS/DB. In a subset of these MS/DB EGFP fibres, red fluorescence resulting from AAV1/2-Rln3-mCherry transduced NI neurons was also present ([Fig. 2](#fig0010){ref-type="fig"}C), confirming relaxin-3 NI neurons send direct projections to the MS/DB. High-magnification confocal images in MS also revealed fine structures containing EGFP and mCherry-IR fluorescence, indicative of potential axon terminals or boutons ([Fig. 2](#fig0010){ref-type="fig"}B-D). Of particular note, given existing evidence for RXFP3 mRNA expression by vGAT mRNA-positive MS neurons, many of the putative relaxin-3 NI (mCherry-positive) nerve terminals were observed in close apposition to MS neurons containing GABA-IR ([Fig. 2](#fig0010){ref-type="fig"}C).Fig. 2*Visualisation of AAV1/2-Rln3-mCherry transduced NI projections, with close apposition to GABAergic neuronal soma in the medial septum*. Fluorescent protein expression was visualised in efferent fibres projecting from transduced NI neurons to the medial septum/diagonal band complex (MS/DB) of rats which received AAV1/2-Rln3-mCherry and AAV1/2-CAG-EGFP injections (**(A)**; EGFP, *green*; mCherry-IR, *red*; Hoechst nuclear stain, *blue*; representative image from n = 2 rats). **(B--D)** In addition to larger fibres passing through the MS which contained both mCherry-IR and EGFP (yellow arrowhead), or EGFP alone (green arrowheads), fine processes and potential terminals from transduced NI neurons were observed in close apposition to neuronal soma containing GABA-IR (*white*; putative contacts indicated by white arrowheads). Representative images of merged (**D**) or separate non-specific EGFP (**B**) and relaxin-3 promoter dirven mCherry-IR (**C**) channels highlight the ability of this approach to provide targeted mapping of fibres and terminals projecting from transduced relaxin-3 NI neurons. Abbreviations: *aca*, anterior commissure, anterior part; *cc*, corpus callosum; *HDB*, nucleus of the horizontal limb of the diagonal band; *IR*, immunoreactivity; *Ld*, lambdoid septal zone; *LV*, lateral ventricle; *MS*, medial septum; *VDB*, nucleus of the vertical limb of the diagonal band.Fig. 2

TrkA is co-expressed with relaxin-3 in rat NI neurons {#sec0065}
-----------------------------------------------------

In parallel to studies characterising the relaxin-3 promoter, we investigated whether a TrkA promoter sequence could be used for targeted transduction of relaxin-3 neurons. Dense immunostaining of TrkA has previously been detected in the clearly distinguishable neurons that comprise the rat NI, despite the fact that this anatomical structure was incorrectly identified as the *prepositus hypoglossal nucleus* in that report (see Fig. 11, ([@bib0320])). The *prepositus hypoglossal nucleus* also expresses dense TrkA mRNA and immunoreactivity ([@bib0085]; [@bib0320]), but it is clearly distinct and distinguishable from the NI. In extending and clarifying these earlier studies, we performed dual immunohistochemistry for TrkA and relaxin-3 to assess their degree of co-expression in NI neurons (n = 5 rats). As expected, immunofluorescence detection revealed TrkA immunoreactive neurons throughout the NI ([Fig. 3](#fig0015){ref-type="fig"}B) and most, if not all, of these neurons also displayed relaxin-3 immunofluorescence ([Fig. 3](#fig0015){ref-type="fig"}A,C). Furthermore, an overlay of TrkA and relaxin-3 immunofluorescence staining in separate, adjacent sections revealed an identical neuronal co-distribution, despite some differences in the subcellular distribution of the immunoreactive materials ([Fig. 3](#fig0015){ref-type="fig"}D-F). This co-expression is consistent with identified roles for NGF/TrkA signalling in supporting the survival and function of key projection-neuron networks, such as cholinergic basal forebrain and GABAergic septohippocampal systems ([@bib0275]; [@bib0065]), and provided the basis for studies of TrkA promoter specificity in rat NI.Fig. 3*Co-expression of relaxin-3 and TrkA immunoreactivity in rat NI*. Overview of immunofluorescence for relaxin-3 (RLN3) (**A**, magenta) and TrkA (**B**, green) in the NI, with a merged image revealing the strong co-expression and resultant overlap of channels (**C**, white). High magnification images of individual (**D**, **E**) and merged (**F**) relaxin-3 and TrkA immunoreactivity show differences in the subcellular distribution of these co-expressed gene products in NI neurons. Abbreviations: *4V*, fourth ventricle; *DTg*, dorsal tegmental nucleus; *IR*, immunoreactivity; *mlf*, medial longitudinal fasciculus; *NIc*, NI *pars compacta*; *NId*, NI *pars dissipata*.Fig. 3

TrkA promoter drives non-specific transgene expression in dorsal pons of adult rats {#sec0070}
-----------------------------------------------------------------------------------

As described for rats receiving AAV1/2-Rln3-mCherry injections, inclusion of data from rats co-injected with AAV1/2-TrkA-mCherry and AAV1/2-CAG-EGFP in the final analyses ([Fig. 4](#fig0020){ref-type="fig"}, n = 3) was dependent on successful bilateral transduction by these vectors throughout the NI. No significant difference was observed in the efficiency of relaxin-3 NI neuronal transduction by AAV1/2-CAG-EGFP in these rats (63 ± 6%; *P* =  0.33 (Student's t-test)) compared to the Rln3 promoter cohort. However, due to some variation in spread of injected vectors to regions surrounding the NI, the calculated specificity for AAV1/2-CAG-EGFP in this group (18 ± 1%, [Fig. 4](#fig0020){ref-type="fig"}G) was slightly lower. A similar distribution of non-specificially transduced neurons in NI and adjacent regions was observed for AAV1/2-TrkA-mCherry ([Fig. 4](#fig0020){ref-type="fig"}B, F), resulting in only 11 ± 1% of mCherry-IR neurons containing relaxin-3-IR. Differences in TrkA and CAG promoter activity within the NI ([Fig. 4](#fig0020){ref-type="fig"}C-E) resulted in a relatively low calculated efficicency as well, with AAV1/2-TrkA-mCherry transducing around one-third (32 ± 8%) of relaxin-3-IR NI neurons. Additional TrkA immunolabelling (data not shown) confirmed widespread transduction of neurons lacking TrkA immunoreactivity by AAV1/2-TrkA-mCherry in these rats.Fig. 4*Neuronal transduction by AAV1/2-TrkA-mCherry*. **(A)** Schematic design of recombinant AAV genomes for AAV1/2-CAG-EGFP and AAV1/2-TrkA-mCherry vectors (*L-ITR*, left inverted terminal repeat; *WPRE*, woodchuck hepatitis virus post-transcriptional regulatory element; *polyA*, SV40 poly A sequence; *R-ITR*, right inverted terminal repeat). **(B)** Representative image of innate fluorescence detected from EGFP (green), together with fluorescent immunoreactivity for mCherry (red) and relaxin-3 (blue), eight weeks after stereotaxic injection of AAV1/2-CAG-EGFP and AAV1/2-TrkA-mCherry vectors targeting NI (*4V*, fourth ventricle; *DTg*, dorsal tegmental nucleus; *mlf*, medial longitudinal fasciculus; *NIc*, NI *pars compacta*; *NId*, NI *pars dissipata*). **(C--E)** Individual fluorescence channels from **(B)** illustrated at higher magnification, revealing neurons lacking relaxin-3 immunoreactivity (RLN3-IR) transduced by AAV1/2-CAG-EGFP only (green arrowheads), AAV1/2-TrkA-mCherry only (mCherry - red fluorescent protein immunoreactivity (RFP-IR); red arrowheads), and both AAV1/2-CAG-EGFP and AAV1/2-TrkA-mCherry (yellow arrowhead). **(F)** Distribution of neurons transduced by AAV1/2-CAG-EGFP (green) or AAV1/2-TrkA-mCherry (red) vectors, compared to the distribution of RLN3-IR (blue) at bregma -9.36 mm, in rats used in the analysis (n = 3). **(G)** Quantification of promoter specificity (proportion of transduced neurons containing RLN3-IR; black circles) and efficiency (proportion of total RLN3-IR neurons transduced; grey circles). Data points for each variable represent individual rats (n = 3) and bars represent mean ± SEM.Fig. 4

Discussion {#sec0075}
==========

Ascending relaxin-3 neurons form abundant connections with key mid- and fore-brain targets. In the rat, these connections are likely maintained by retrograde NGF signalling via TrkA ([@bib0110]), in light of the observed selective expression of TrkA with relaxin-3. Previous reports of cell-type specific transgene expression using TrkA promoter elements in other species and contexts ([@bib0045]; [@bib0290]; [@bib0200]) suggested this approach could allow targeted viral vector transduction of rat TrkA/relaxin-3 NI neurons. However, an AAV vector engineered to express mCherry under the control of an 880 bp TrkA promoter sequence failed to provide cell-type specific expression in rat NI. In contrast, using a previously uncharacterised 1736 bp relaxin-3 promoter sequence, we were able to efficiently transduce relaxin-3 NI neurons with 98% specificity.

Several technical obstacles must be overcome to successfully use promoter sequences to achieve cell-type specific transgene expression from a viral vector. Viral vectors have a limited packaging capacity, with AAV vectors failing to incorporate recombinant genomes larger than ∼4.7 kb ([@bib0365]). Feasible promoter candidates must therefore be restricted to several kilobases or less, depending on the vector used. As a result, loss of regulatory elements such as histone binding sites, located potentially tens of kilobases upstream from the gene coding sequence of interest, can be a major impediment to this experimental approach. Cell-type specific promoters also need to be able to suppress expression driven by the AAV inverted terminal repeat (ITR) sequences. These ITRs, which are essential for AAV genome packaging, can drive transgene expression independently of other promoter elements ([@bib0070]). Furthermore, high viral vector titres can reduce transduction specificity by increasing the number of genomic copies introduced to a cell, thus amplifying any weak, non-specific promoter activity ([@bib0135]). As alternative vector titres or volumes were not tested, this is an important consideration for the use of these and similar vectors in future studies. The potential for variations in transcription factor expression and/or epigenetic modifications due to cellular environment and context is also a key consideration when validating the suitability of promoters for their intended applications.

One or more of these factors may have led to the non-specific activity observed for the 880 bp rat TrkA promoter. Previous studies have identified a minimal promoter region of ∼150 bp, directly upstream of human ([@bib0045]) and mouse ([@bib0290]) TrkA coding sequences, which provided cell-type specific transgene expression in cultured neuroblastoma cells following transient transfection. A conserved TrkA enhancer was also shown to provide cell-type specific transgene expression from a pronuclear-injected plasmid construct, independently of the minimal promoter, in trigeminal and dorsal root ganglia of P0 mouse pups ([@bib0200]). Although the 880 bp rat TrkA promoter region used in our AAV1/2-TrkA-mCherry vector contained regions analogous to these human and mouse minimal promoter and mouse enhancer sequences, with 59%, 96% and 87% sequence identity, respectively, we were unable to replicate the targeted expression reported *in vitro* and in P0 mice. In addition to targeting neurons in the adult rat brainstem, rather than developing mouse ganglia or cell culture, our recombinant AAV genomes by necessity contain ITR sequences that were absent from the plasmids used in earlier studies. The incorporation of further sequence 5′ to the 880 bp promoter tested may capture elements sufficient to provide cell-type specific expression, but as mentioned, would eventually be limited by the AAV vector packaging capacity.

However, the AAV1/2-Rln3-mCherry vector, containing a 1736 bp rat relaxin-3 promoter region, provided highly targeted transduction of relaxin-3 NI neurons. Transgene expression mediated by this vector was localised to the NI, where 98% of mCherry transduced neurons also contained relaxin-3 immunoreactivity. This was despite non-specific transduction of DTg and closely adjacent, non-relaxin-3 neurons in NI by co-injected AAV1/2-CAG-EGFP, emphasising that the specificity of the AAV1/2-Rln3-mCherry vector was achieved through promoter-mediated control of transgene expression and not viral vector tropism. Notably, one outcome that was apparently due to AAV1/2 vector tropism was a consistent transduction efficiency of around 70% of relaxin-3 NI neurons (with the exception of AAV1/2-TrkA-mCherry). Although alternative approaches, such as equivalent transgenic mouse or rat lines, may increase this efficiency, a purely viral vector-based methodology offers highly flexible options in targeting particular relaxin-3 neuron populations at specific time points during the lifespan of rats or mice. In the future, it will also be of interest to investigate the use of the relaxin-3 promoter vector to study the function of the smaller and more dispersed relaxin-3 neuron populations in the pontine raphe, PAG and dorsal to substantia nigra. Detailed analysis of the neurochemistry of transduced relaxin-3 neurons and their efferent connections, as demonstrated here in the MS/DB, will be valuable in determining the implications of targeted functional studies, that extend those using constitutively active promoters ([@bib0205]; [@bib0325]).

The future utility of a relaxin-3-specific promoter is wide-ranging in nature. In the current study, targeted transgene expression was validated eight weeks after viral vector injection, indicating this approach would be suitable for physiological and behavioural studies within similar, if not potentially longer, time frames. New AAV constructs designed to include the relaxin-3 promoter would be able to accommodate at least 1.6 kb of transgene coding sequence. Many transgenes commonly used in modern neuroscience, including genetically-encoded calcium indicators (around 1.3 kb; [@bib0340]) and fluorescently-tagged opsins (around 1.6 kb; [@bib0025]), could readily be expressed directly from an AAV vector under this relaxin-3 promoter. An AAV1/2 capsid was used here, as we have previously established its favourable tropism towards NI neurons ([@bib0035]), but other vectors such as lentivirus could be explored as a means of increasing packaging capacity for transgene cargo. Additional AAV packaging space could also be gained through the use of condensed polyadenylation and posttranscriptional regulatory elements ([@bib0050]), and further refinement of the relaxin-3 promoter itself. Although beyond the scope of this study, determining the particular motifs that confer cell-type specificity may allow engineering of a more compact promoter, improving transgene packaging capacity as well as promoter compatibility with transcriptional amplification strategies ([@bib0190]). Furthermore, such endeavours could also provide insights into relaxin-3 gene regulation, similar to those reported in response to CRF signalling ([@bib0335]).

In conclusion, following transduction by an injected AAV vector targeting the NI, we observed widespread non-specific mCherry transgene expression driven by an 880 bp TrkA promoter sequence in the adult rat brainstem. Differences in cell context, species and/or method of transgene delivery may explain discrepancies between our data and previous reports of selective expression driven from analogous promoter or enhancer regions in neuroblastoma cell lines and developing mouse nervous system. Notably, we also identified a novel cell-type specific relaxin-3 promoter, capable of transducing relaxin-3 NI neurons with 98% specificity for at least 8 weeks after AAV vector injection. Future studies utilising this promoter should lead to further insights into the molecular mechanisms that regulate relaxin-3 gene expression. Importantly, this newly characterised promoter sequence also represents a versatile tool for targeted studies of relaxin-3 circuitry in ongoing preclinical research.
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